Table 4 Mean, median and spread of outcome measurements by participant groups
From: Circulating levels of GDF15 in patients with myalgic encephalomyelitis/chronic fatigue syndrome
Instrument | Healthy controls | Multiple sclerosis | ME/CFS mild/moderate | ME/CFS severe symptoms | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mean | SD | Median | IQR | Mean | SD | Median | IQR | Mean | SD | Median | IQR | Mean | SD | Median | IQR | |
FSS | 20.1 | 9.22 | 18 | 14–25 | 46.7 | 14.3 | 51 | 37–58 | 57.3 | 6.7 | 59 | 54–63 | 59.2 | 3.5 | 60 | 57–62 |
PAS | 0.96 | 1.46 | 0.5 | 0–1.2 | 3.4 | 2.7 | 3 | 0.7–6.2 | 4.9 | 2.4 | 5.3 | 3.1–6.9 | 5.4 | 2.6 | 6 | 3.2–7.5 |
PCS | 57.1 | 4.9 | 58.1 | 55.9–60.3 | 38.3 | 12.3 | 36.9 | 28.5–48.3 | 39.1 | 9.9 | 40.4 | 32.6–46.3 | 19.1 | 4.8 | 19.8 | 15.6–22.2 |
MCS | 52.1 | 8.1 | 54.9 | 49.6–57.6 | 46.0 | 10.8 | 47.5 | 38.5–54.6 | 59.2 | 3.6 | 60 | 57–62 | 44.0 | 9.9 | 45.6 | 38.4–51.1 |